Clinical Trials
The Chase Family Movement Disorders Center continues to seek new ways to slow the progression of neurodegenerative disorders through clinical trials in collaboration with other movement disorders specialists throughout North America.
We have several ongoing clinical research studies as noted below, and all patients have the option to participate in one or more clinical trials. We are also involved in mentoring physicians-in-training who will serve the community in the future as neurologists or in primary care.
1. Protocol No: TOZ-CLO5 (actively enrolling) “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose Wearing-Off.”
2. Protocol No: 16306A (actively enrolling) “RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy”.
3. Protocol No: IN 11 004 (enrolling in Fall 2016) “A phase III, multicenter, randomized, double-blind, double-dummy, active-controlled study comparing the efficacy and safety of gastric retentive, controlled release Accordian pill™ carbidopa/levodopa (AP CD/LD) to immediate release CD/LD in fluctuating Parkinson's disease patients."
4. Protocol No: INO-PD-P3-2014 (enrolling in Fall 2016): A randomized, double-blind, placebo-controlled trial of urate elevating Inosine treatment to slow clinical decline in early Parkinson’s disease (PD). Abbreviated Study Name: SURE-PD3 (Study of URate Elevation in PD, phase 3).